Tumor Biology

, 32:1071

HLA-G regulators in cancer medicine: an outline of key requirements

Authors

    • Sciences CollegeKing Faisal University
    • Laboratory of Biochemistry, Research Unit 02/UR/09-01Higher Institute of Biotechnology of Monastir
  • Nidhal Ben Amor
    • Sciences CollegeKing Faisal University
Review

DOI: 10.1007/s13277-011-0213-2

Cite this article as:
Zidi, I. & Ben Amor, N. Tumor Biol. (2011) 32: 1071. doi:10.1007/s13277-011-0213-2

Abstract

HLA-G is unique among the class I human leukocyte antigens. It plays a pivotal role in immune tolerance and a paradoxical role in therapies. Indeed, HLA-G expression is associated with a good prognosis in organ transplantation and an ominous prognosis in cancer. Recent progress has been made in HLA-G regulation identification, especially on human cell lines; however, little is known about their role in cancer therapy. Based on the role of HLA-G expression in cancer, we investigated the potential impact of the regulation of this expression on the outcome of some cancers. In this communication, we emphasize the importance of screening for HLA-G expression after cancer therapy. Future clinical trials could lead to a better understanding of the implication of HLA-G expression in cancer and lead to a better knowledge of cancer monitoring and recurrence. These studies could also implicate HLA-G as a therapeutic target in cancer therapy.

Keywords

HLA-GCancerTherapyRegulatorsModulation

Abbreviations

1MDT

1-Methyl-d-tryptophan

DC

Dendritic cells

DFX

Desferrioxamine

FDA

Food and Drug Administration

GM-CSF

Granulocyte macrophage colony-stimulating factor

HDAC

Histone deacetylase

HLA-G

Human leukocyte antigen-G

IDO

Indoleamine 2,3-dioxygenase

IFN

Interferon

IL

Interleukin

ILT

Immunoglobulin-like transcript

KIR

Killer inhibitory receptor

sHLA-G1

Shedding of HLA-G1

sHLA-G

Soluble HLA-G

TNF

Tumor necrosis factor

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011